Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Cytoskeletal Signaling >  PAK inhibitors >  IPA-3

IPA-3

Basic information Safety Supplier Related

IPA-3 Basic information

Product Name:
IPA-3
Synonyms:
  • 1,1'-Dithiodi-2-naphthtol
  • IPA 3
  • p21-Activated Kinase Inhibitor III, IPA-3
  • Bis(2-hydroxy-1-naphthyl) disulfide
  • 2-Naphthalenol, 1,1'-dithiobis-
  • 1,1′-Disulfanediyldinaphthalen-2-ol
  • IPA 3;IPA3
  • p21-Activated Kinase Inhibitor III, IPA-3 - CAS 42521-82-4 - Calbiochem
CAS:
42521-82-4
MF:
C20H14O2S2
MW:
350.45
Product Categories:
  • Inhibitors
  • PAK Inhibitor III, IPA-3
  • 1,1'-disulfanediylbis(naphthalen-2-ol)
  • PAK Inhibitor III
Mol File:
42521-82-4.mol
More
Less

IPA-3 Chemical Properties

Melting point:
172℃
Boiling point:
543.7±35.0 °C(Predicted)
Density 
1.46±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: >20mg/mL
pka
7.52±0.50(Predicted)
form 
Yellow solid
color 
off-white to yellow
Water Solubility 
Soluble in DMSO or ethanol. Insoluble in water.
Sensitive 
Light Sensitive
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
CAS DataBase Reference
42521-82-4
More
Less

Safety Information

Hazard Codes 
Xi,N
Risk Statements 
41-50/53
Safety Statements 
26-39-60-61
RIDADR 
UN 3077 9 / PGIII
WGK Germany 
3
HazardClass 
9
More
Less

IPA-3 Usage And Synthesis

Description

IPA-3 (42521-82-4) is a selective allosteric inhibitor of Group 1 p21-activated kinase (PAK1 IC50?= 2.5 μM)1?via covalent binding to the PAK1 regulatory domain preventing binding to the upstream activator Cdc422. IPA-3 has been shown to induce cell death in human leukemic cell lines3, significantly inhibit TGFβ1-induced prostate cell epithelial to mesenchymal transition4?and inhibit the growth of liver cancer cells5.

Uses

p21-activated kinase 1 (PAK1) is a member of a family non-receptor serine/threonine kinases that are vital to normal cell function. Binding of various upstream partners to PAK1 results in release of an autoinhibitory domain that blocks activity of the kinase domain. PAK1 expression and activity is upregulated in several human cancers and is a potential therapeutic target for cancer intervention. IPA-3 is a cell-permeable allosteric inhibitor of PAK1 that is non-competitive with respect to ATP binding (IC50 = 2.5 μM). It does not, however, inhibit the activity of PAK1 that has been pre-activated with Cdc42. IPA-3 binds covalently to the PAK1 regulatory domain (apparent Kd = 1.9 uM) and prevents binding to the upstream activator Cdc42.[Cayman Chemical]

Uses

Acts as an allosteric inhibitor of Pak1

Definition

ChEBI: An organic disulfide obtained by oxidative dimerisation of 1-sulfanylnaphthalen-2-ol.

Biological Activity

IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).

Biochem/physiol Actions

IPA-3 is an allosteric inhibitor of Pak1. It binds to autoinhibitory domain of Pak1 (p21 activated kinase), highly selective amongst kinases. Pak1 is implicated in tumorigenesis and metastasis.

in vitro

IPA-3 is a non ATP-competitive, allosteric inhibitor of p21-activated kinase 1 (Pak1). PIR3.5 is the control compound of IPA-3. IPA-3 prevents Cdc42-stimulated Pak1 autophosphorylation on Thr423. IPA-3 also prevents sphingosine-dependent Pak1 autophosphorylation. IPA-3 does not target exposed cysteine residues on Pak1. The disulfide bond of IPA-3 is critical for inhibition of Pak1 and in vitro reduction by the reducing agent dithiothreitol (DTT) abolishes Pak1 inhibition by IPA-3. IPA-3 inhibits activation of Pak1 by diverse activators, but does not inhibit preactivated Pak1. IPA-3 inhibits PDGF-stimulated Pak activation in mouse embryonic fibroblasts. IPA-3 inhibits Pak1 activation in part by binding covalently to the regulatory domain of Pak1. IPA-3 binds Pak1 covalently in a time- and temperature-dependent manner. IPA-3 prevents binding of the Pak1 activator Cdc42. IPA-3 binds directly to the Pak1 autoregulatory domain. IPA-3 reversibly inhibits PMA-induced membrane ruffling in cells.

storage

Store at -20°C

References

1) Deacon?et al.?(2008)?An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase; Chem.Biol.,?14?322 2) Viaud and Peterson (2009)?An allosteric kinase inhibitor binds the p21-activated kinase (PAK) autoregulatory domain covalently; Mol. Cancer Ther.,?8?2559 3) Kuzelova?et al. (2014)?Group 1 PAK Inhibitor IPA-3 Induces Cell Death and Affects Cell Adhesivity to Fibronectin in Human Hematopoietic Cells; PLoS One,?9?e92560 4) Al-Azayzih?et al.?(2015)?P21 Activated Kinase-1 Mediates Transforming Growth factor b1-Induced Prostate Cancer Cell Epithelial to Mesenchymal transition; Biochim. Biophys. Acta,?1853?1229 5) Wong?et al.?(2013)?IPA-3 Inhibits the Growth of Liver Cancer Cells By Suppressing PAK1 and NF-kB Activation; PLoS One,?8?e68843

IPA-3Supplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
VDM Biochemicals
Tel
0330-2528181
Email
sales@vdmbio.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
More
Less